CMA consults on bipolar drug commitments
Essential Pharma has promised to continue supplying a bipolar drug to UK patients, likely addressing the UK competition authority’s concerns that it abused its dominance by planning to withdraw the medication from the national market.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.